Health body opens market engagement on newborn SCID and SMA workflow
Notice outlines plans to procure SPOT-it methodology for newborn blood spot labs, strengthening national screening for severe genetic conditions.
Notice outlines plans to procure SPOT-it methodology for newborn blood spot labs, strengthening national screening for severe genetic conditions.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
NHS England has signalled plans to buy the SPOT-it methodology for newborn blood spot screening laboratories, to support ongoing evaluations for Severe Combined Immuno-Deficiency (SCID) and Spinal Muscular Atrophy (SMA) within a national programme.
The NHS Labs SCID and SMA Workflow prior information notice, published on 6th March 2026, sets out NHS England’s intention to procure the SPOT-it methodology for use across newborn blood spot screening laboratories. The stated purpose is to enable labs to deliver ongoing evaluations for SCID and SMA as part of a national programme.
Although the notice is brief, it points clearly to a lab-focused procurement. Rather than describing a traditional clinical service contract, NHS England is flagging a specific methodology and workflow for laboratories that handle newborn blood spot samples. The emphasis on “ongoing evaluations” suggests a sustained role in monitoring and assessing how screening for these conditions performs over time, rather than a one-off implementation.
By anchoring SCID and SMA within a national screening programme, the notice underlines the importance attached to early detection of serious, often rare, conditions in newborns. Standardising how laboratories undertake this work, through a defined methodology such as SPOT-it, could help drive greater consistency in test performance, reporting and quality assurance across participating sites.
For potential suppliers, the PIN offers an early indication that NHS England is preparing the ground for a structured purchase that will influence how newborn screening labs operate. The detail on scope, contract model and duration is still to come, but the signal is that any future tender will expect bidders to support a clearly defined workflow focused on these two conditions.
The SCID and SMA workflow notice sits alongside a growing group of procurements that seek not just products, but integrated diagnostic and analytical services. In December 2025, University Hospitals Plymouth NHS Trust published a prior information notice for a digital histopathology service. That procurement aims to secure an end-to-end pathway, including integrated AI diagnostic support and NHS reporting, with a specific focus on the prostate cancer pathway.
Where the Plymouth notice combines equipment, software and reporting into a single pathway contract, NHS England’s newborn screening PIN concentrates on a defined testing methodology used in specialist laboratories. Both, however, highlight commissioners’ interest in solutions that embed technology and method into routine diagnostic workflows rather than treating them as standalone purchases.
In January 2026, the Business Services Organisation Procurement and Logistics Service added to this pattern by opening preliminary market engagement for a managed service contract for point of care testing. Its market engagement for POCT services covers INR and handheld blood gas testing and is structured as a two-stage process to explore supplier capability for a managed service model.
Earlier, in December 2025, NHS Blood and Transplant launched supplier engagement on a supply chain planning solution to improve forecasting, inventory management and operational decision-making across the blood supply chain. That notice, like the newborn screening PIN, focuses on the infrastructure and intelligence that sit behind clinical activity.
Taken together, these procurements show commissioners putting increasing weight on methodologies, digital tools and managed services that support the reliability, efficiency and visibility of diagnostic work. The SPOT-it workflow for SCID and SMA fits this trend by concentrating on how laboratories carry out and evaluate tests within a national programme framework.
The newborn screening workflow also sits within a broader push to strengthen preventive services in the earliest years of life. In December 2025, NHS England North East and Yorkshire (Yorkshire and Humber) published a prior information notice for a Health Visitor Vaccination Pathfinder Project. That project seeks qualified providers to improve uptake of routine childhood immunisations for children aged 0–5 years across designated areas, with participation limited to organisations already holding a Health Visitor Service Contract with the relevant local authority.
Where the vaccination pathfinder focuses on service models and outreach to families, the SCID and SMA workflow targets the laboratory backbone of prevention. Both, however, recognise that getting upstream of serious disease in children depends on reliable systems, from community contacts to specialist diagnostics.
Outside the UK, similar themes are emerging. On 23rd December 2025, Instytut Matki i Dziecka issued a contract notice for screening sets for newborns. The institute is buying reagent kits for screening newborns for severe congenital immune deficiencies and spinal muscular atrophy, using real-time quantitative PCR technology, for a total of 362,880 tests.
The strong overlap in clinical focus with NHS England’s SCID and SMA workflow notice is striking. Both buyers are looking at high-throughput screening for the same conditions in newborns, with one concentrating on reagents and real-time PCR technology and the other on methodology and lab workflow within a national programme. For suppliers active in neonatal screening, these linked opportunities underline growing demand for standardised, scalable solutions that can be embedded into national services.
While the SCID and SMA workflow notice does not set out its route to market in detail, it lands in a commissioning environment where the Provider Selection Regime (PSR) and Most Suitable Provider processes are increasingly visible in health-related procurements.
In October 2025, Cambridgeshire Community Services NHS Trust published a prior information notice for physiotherapy services, stating that the contract would be awarded following the Most Suitable Provider Process under the Health Care Services Provider Selection Regime Regulations. On 14th January 2026, East Kent Hospitals University NHS Foundation Trust signalled a similar approach in its prior information notice for outsourced radiology reporting services and a trial of an operational business intelligence tool, explicitly stating that it would use the Most Suitable Provider process without a competitive exercise.
Local authorities and specialist trusts are also turning to the PSR framework. Southend-on-Sea City Council’s prior information notice of 18th December 2025 for a yoga pilot programme for social prescribing explicitly references the PSR Most Suitable Provider process, as does Sussex Partnership NHS Foundation Trust’s notice for pharmacy medicines supply services, where potential providers have been identified for direct contract awards.
In January 2026, NHS Wales Shared Services Partnership signalled its intention to follow a Most Suitable Provider Process for a level 3 digital weight management service, noting that a provider had already been selected and inviting expressions of interest within a defined timeframe.
For the diagnostics and laboratory market, this wider PSR activity matters because it shapes how clinical and analytical services are packaged and awarded. Even where, as in the SCID and SMA workflow notice, the route to contract is not yet specified, suppliers will be alert to the possibility that methodologies, managed services and clinical pathways may be commissioned through a mix of competitive tenders, framework call-offs and Most Suitable Provider processes.
The SPOT-it newborn screening workflow notice is, at this stage, a signalling exercise rather than a detailed specification. It confirms NHS England’s intention to procure a defined methodology for laboratory evaluations of SCID and SMA within a national programme, but leaves open key questions about contract structure, volumes, timelines and participation criteria.
Suppliers active in newborn screening, molecular diagnostics and laboratory workflow solutions will be watching for a follow-up contract notice or further market engagement that clarifies:
Alongside this, the cluster of recent procurements in digital histopathology, supply chain planning and point of care testing shows that commissioners are increasingly interested in joined-up, data-rich laboratory services. The forthcoming details of NHS England’s SCID and SMA workflow procurement will indicate how far newborn screening is set to follow the same path.
For now, the 6th March 2026 prior information notice marks an important step in shaping how newborn blood spot laboratories across the system approach SCID and SMA testing, and it gives the laboratory and life sciences market an early signal of where future demand is likely to fall.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.